Sign up to our newsletter Subscribe
Understanding societal preferences for priority by disease severity in England & Wales
< 1 min read|01/12/2016
Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL.
Stakeholders’ involvement in Health Technology Assessment (HTA) can take different forms. Multi-criteria decision analysis (MCDA) offers systematic ways to collect evidence on how stakeholders make trade-offs between decision criteria and to consider this evidence in decision making.
In this study we applied an MCDA framework (EVIDEM V3.0) to derive views and preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and using these to assess the value of obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL).
Please note a version of this paper has also been published in PharmacoEconomics (open).
Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Garau, M., Marsden, G., Devlin, N., Amedeo Mazzanti, N. and Profico, A. (2016) Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).
OHE Grant-Funded Research. Available from https://www.ohe.org/publications/applying-multi-criteria-decision-analysis-mcda-approach-elicit-stakeholders/
